July 26, 2014 3:51 PM ET

Biotechnology

Company Overview of Intrexon Corporation

Company Overview

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field. Synthetic biology is a discipline that applies engineering principles to biological systems. The company designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components using its proprietary and complementary technologies. Its proprietary and complementary technologies comprise UltraVector gene design and fabrication platform, which is an integrated suite of tools comprising DNA construction technology and components, cellular and protein engineering tools, computational models, and statistical methods; Cell systems informatics, a bioinformatics software and da...

222 Lakeview Avenue

Suite 1400

West Palm Beach, FL 33401

United States

Founded in 1998

223 Employees

Phone:

561-410-7000

Key Executives for Intrexon Corporation

Chairman
Age: 60
Founder and Chief Science Officer
Age: 48
Total Annual Compensation: $499.2K
Chief Operating Officer
Age: 49
Total Annual Compensation: $2.1M
Senior Vice President of Energy & Chemicals Sector and President of Industrial Products Division
Age: 56
Total Annual Compensation: $341.0K
Executive Vice President of Scientific & Public Affairs
Age: 68
Total Annual Compensation: $485.3K
Compensation as of Fiscal Year 2013.

Intrexon Corporation Key Developments

Intrexon Names Christopher Basta Vice President of Investor Relations

Intrexon Corporation announced the appointment of Christopher Basta as Vice President of Investor Relations, effective immediately. Mr. Basta will report directly to Chairman and Chief Executive Officer Randal J. Kirk. Mr. Basta brings more than 18 years of financial experience to Intrexon. Most recently, he was a consultant for DSP Group directing its investor relations initiatives.

Intrexon Corporation Presents at World Congress on Industrial Biotechnology, May-12-2014

Intrexon Corporation Presents at World Congress on Industrial Biotechnology, May-12-2014 . Venue: Philadelphia, Pennsylvania, United States.

Intrexon Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Intrexon Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net income attributable to Intrexon of $4.1 million, or $0.04 per basic and diluted share compared to net loss attributable to Intrexon of $36.3 million or $7.54 basic and diluted for the quarter ended March 31, 2013. Adjusted EBITDA was $17.6 million, or $0.18 per basic and diluted share compared to adjusted LBITDA of $7.0 million or $0.09 per basic and diluted share for the quarter ended March 31, 2013. Total revenues were $7.9 million compared to $3.9 million for the quarter ended March 31, 2013, an increase of $4.0 million, or 102.2%. Operating loss was $17.872 million against $14.006 million a year ago. Income before tax was $3.555 million against loss before tax of $36.362 million a year ago. Net income attributable to common shareholders was $4.115 million against net loss attributable to common shareholders of $42.716 million a year ago. EBITDA was $6.218 million against LBITDA of $34.429 million a year ago.

Similar Private Companies By Industry

Company Name Region
Tidal Air, Inc. United States
Amgen Manufacturing, Limited United States
The Institute For Cancer Research United States
Direct Spinal Therapeutics, Inc. United States
Aura Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 1, 2014
Trans Ova Genetics LC
Private Placement
March 26, 2014
--
Merger/Acquisition
March 13, 2014
Codexis Laboratories Hungary Kft.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intrexon Corporation, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.